rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

NRX Pharmaceuticals, Inc.

NRXP · Nasdaq

Health CareBiotechnologyNot moving yet

NRXP stood above a rising 150-day average in 19 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 19.7% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 4
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
44 (+14)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 19 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$45KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders44+14 on the quarter
New · exited19 · 5
Reported value$47.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
B Group, Inc.added · filed 14 Aug 20264,091,767$16.7M+1,091,767+36.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,618,159$6.6M+457,975+39.5%
AMERIPRISE FINANCIAL INCnew · filed 14 Aug 2026928,728$3.8M+928,728
Balyasny Asset Management L.P.new · filed 14 Aug 2026893,864$3.7M+893,864
CITADEL ADVISORS LLCnew · filed 14 Aug 2026680,043$2.8M+680,043
AdvisorShares Investments LLCadded · filed 11 Aug 2026659,018$2.7M+238,551+56.7%
COMMONWEALTH EQUITY SERVICES, LLCadded · filed 29 Jul 2026454,418$1.9M+56,987+14.3%
UBS Group AGadded · filed 13 Aug 2026423,115$1.7M+397,888+1577.2%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026314,659$1.3M+4,547+1.5%
BlackRock, Inc.added · filed 7 Aug 2026220,460$902K+121,465+122.7%
30 Jun 2024 – 30 Jun 2026
193143Jun 24Dec 24Jun 25Dec 25Jun 26

Everyone who traded it

Joseph Michael Casper Company insiderChief Operating Officer · last 27 Jan 20260 · 0
Chaim Hurvitz Company insiderDirector · last 9 Apr 20257 · 0
Dennis McBride Company insiderDirector · last 9 Apr 20250 · 0
Jonathan C. Javitt Company insiderChairman and Chief Scientist · last 9 Apr 20255 · 1
Patrick John Flynn Company insiderDirector · last 9 Apr 20251 · 0
Michael S. Abrams Company insiderChief Financial Officer · last 7 Feb 20250 · 0
Aaron Gorovitz Company insiderDirector · last 30 Aug 20231 · 0
Stephen H. Willard Company insiderCHIEF EXECUTIVE OFFICER · last 16 Dec 20221 · 0
Voorhees Seth Van Company insiderCHIEF FINANCIAL OFFICER · last 16 Dec 20223 · 0
Daniel C. Javitt Company insider10% owner · last 30 Nov 20220 · 9
Sharon Glied Company insiderDirector · last 21 Oct 20220 · 0
Robert Besthof Company insiderInterim CEO · last 8 Mar 20220 · 1

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202558.8%
Research spendFY 2025 · to 31 Dec 2025308%
Share count trendFY 2025 · to 23 Mar 20264.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$7.8M

Analyst forecasts

No analyst forecasts yet.